A Phase 2a, Randomized, Double-blind, Vehicle-controlled Study, To Characterize The Mechanism Of Action Of Crisaborole Ointment 2%, By Evaluation Of Efficacy And Changes In Skin Biomarkers, In Adult Subjects With Mild To Moderate Atopic Dermatitis, With A 4 Week Open-label Extension

Trial Profile

A Phase 2a, Randomized, Double-blind, Vehicle-controlled Study, To Characterize The Mechanism Of Action Of Crisaborole Ointment 2%, By Evaluation Of Efficacy And Changes In Skin Biomarkers, In Adult Subjects With Mild To Moderate Atopic Dermatitis, With A 4 Week Open-label Extension

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Crisaborole (Primary)
  • Indications Atopic dermatitis
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 12 Apr 2018 Planned End Date changed from 12 May 2018 to 7 May 2018.
    • 12 Apr 2018 Planned primary completion date changed from 12 May 2018 to 7 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top